Clinical TrialJun 5, 2026, 07:36 PM
MannKind Presents New Afrezza & FUROSCIX Data at ADA Scientific Sessions
AI Summary
MannKind Corporation announced new clinical and real-world data for Afrezza (insulin human) Inhalation Powder and FUROSCIX (furosemide injection) to be presented at the American Diabetes Association's 2026 Scientific Sessions. The data reinforces Afrezza's established safety and efficacy, particularly in pediatric patients following its recent FDA approval, and highlights benefits beyond glycemic control. Findings also support Afrezza's potential use in gestational diabetes and provide insights into its use with automated insulin delivery systems, while FUROSCIX data showed reduced hospitalizations in heart failure patients.
Key Highlights
- Afrezza showed greater treatment satisfaction in youth with HbA1c <8% compared to rapid-acting analogs (RAA).
- Afrezza achieved non-inferior mean HbA1c compared to RAA in youth with baseline HbA1c "u22649.5% after 26 weeks.
- In gestational diabetes, Afrezza demonstrated comparable efficacy to RAA with nominally reduced postprandial glucose excursions and fewer hypoglycemic events.
- Inhaled insulin delivers over 50% of its pharmacodynamic effect within 60 minutes, compared to 10% for Lispro.
- FUROSCIX treatment showed lower hospitalization rates and longer time to hospitalizations in heart failure patients with fluid overload.
- No increased incidence of lung cancer was observed among inhaled insulin users compared to other insulin treatment cohorts in adults with type 2 diabetes.
- Increased Medicare Part D utilization for Afrezza was observed following the implementation of the insulin cost cap under the Inflation Reduction Act.
Price Impact
More from MNKD